CUMBERLAND PHARMACEUTICALS INCCPIX

CUMBERLAND PHARMACEUTICALS INC Revenue Disclosure

10-KFiled Mar 9, 20262 min read
Revenues
Product Revenue
The Company’s net product revenues consisted of the following for the years ended December 31:
20252024
Products:
Sancuso11,907,141 9,005,129 
Kristalose10,542,793 15,315,259 
Vibativ9,484,874 7,160,125 
Caldolor4,659,457 4,959,385 
Talicia3,311,235 — 
Acetadote508,169 185,182 
Vaprisol(18,346)(174,538)
RediTrex11,391 90,237 
Omeclamox(10,436)(3,075)
Other4,125,153 1,330,241 
Total net revenues$44,521,431 $37,867,945 
Other Revenues
The Company has agreements with international partners for commercialization of the Company’s products with associated payments included in other revenues. Those agreements provide that each of the partners is responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
In the first and third quarters of 2025, the Company received $3.1 million relating to milestone payments received from our international partners which is included in other revenues.
Other revenues includes funding from federal grant programs including those secured from the FDA and from those secured by CET through the Small Business Administration. Grant revenue from these federal grant programs totaled approximately $0.4 million for the years ended December 31, 2024. There was no grant revenue for the year ended December 31, 2025.
Other revenues also includes lease income generated by CET’s Life Sciences Center. It is a research facility that provides scientists with access to flexible lab space and other resources to develop biomedical products. This lease income, as noted in Footnote 15 - Leases, was approximately $0.7 million and $0.6 million and for the years ended December 31, 2025 and 2024, respectively.
Free Sentinel

Want the next CUMBERLAND PHARMACEUTICALS INC revenue disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment CUMBERLAND PHARMACEUTICALS INC's next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Mar 9, 2026Showing above
2024Mar 7, 2025
2023Mar 13, 2024
2022Mar 13, 2023
2021Mar 11, 2022
2020Mar 12, 2021
2019Mar 20, 2020
2018Mar 12, 2019
2017Mar 9, 2018
2016Mar 13, 2017
2015Mar 14, 2016

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&EGoodwill & IntangiblesLeasesDebtCommitmentsStock CompensationNew StandardsPay vs Performance